Bristol Myers breaks the bank on Eisai's folate receptor ADC drug, laying out more than $3B+ for rights
For years, innovation in oncology has been a crapshoot with Big Pharma — the whales at the table — dropping the big bucks for the key to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
